Thus, according to ARMS–HRMA, KRAS mutations in tumor samples were as follows: WT in 20, G12D in 32, G12V in 22, G12D/G12V in 2, G12R in 10, G12C in 1, and G12D/G12C in 1 patient. This evidence concerns the gene KRAS and neoplasm.